<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932655</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-125-05</org_study_id>
    <nct_id>NCT04932655</nct_id>
  </id_info>
  <brief_title>Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers</brief_title>
  <official_title>A Four-way Crossover Food Effect and Bioequivalence Pharmacokinetic Study of Simufilam in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cassava Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cassava Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, four-treatment, four-sequence crossover study in healthy&#xD;
      volunteers to estimate the effect of food on the PK of simufilam following oral 100 mg doses&#xD;
      and to estimate its relative bioavailability compared to the earlier Phase 2 simufilam tablet&#xD;
      in the fasted state. A total of twenty four (24) healthy volunteers (12 male and 12 female)&#xD;
      will be enrolled into this study. Subjects will be randomly assigned to one of four treatment&#xD;
      sequences (6 subjects/sequence).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will compare the PK of the Phase 3 simufilam 100 mg oral tablet when taken fasted&#xD;
      versus following a high-fat or low-fat meal. Additionally, the Phase 3 oral tablet will be&#xD;
      compared to the Phase 2 oral tablet for bioequivalence under fasted conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Actual">May 12, 2021</completion_date>
  <primary_completion_date type="Actual">May 12, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Four-way crossover of Phase 3 tablets under fasted or high-fat or low-fat conditions and the Phase 2 tablet under fasted conditions. Subjects are randomized to a sequence.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>The maximum concentration determined directly from individual concentration-time data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 hours</time_frame>
    <description>Time to reach maximum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the curve to the time of the last quantifiable concentration, calculated using the linear trapezoidal method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>24 hours extrapolated to infinity</time_frame>
    <description>Area under the curve extrapolated to infinity; calculated as: AUCinf = AUClast + Clast/λz</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clast</measure>
    <time_frame>24 hours</time_frame>
    <description>The last quantifiable concentration determined directly from individual concentration-time data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tlast</measure>
    <time_frame>24 hours</time_frame>
    <description>Time of the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>λz</measure>
    <time_frame>24 hours</time_frame>
    <description>The observed elimination rate constant; estimated by linear regression through at least three data points in the terminal phase of the log concentration-time profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>24 hours</time_frame>
    <description>The observed terminal elimination half-life calculated as: T1/2 = ln(2)/λz</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fasted</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 3 simufilam 100 mg tablet dosed under fasted conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Fat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 3 simufilam 100 mg tablet dosed 30 min after start of a high-fat meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Fat</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 3 simufilam 100 mg tablet dosed 30 min after start of a low-fat meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 tablet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 2 simufilam 100 mg tablet dosed under fasted conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simufilam</intervention_name>
    <description>Simufilam 100 mg oral tablets: the Phase 3 oral tablet for the first 3 arms and the Phase 2 tablet for the 4th arm.</description>
    <arm_group_label>Fasted</arm_group_label>
    <arm_group_label>High Fat</arm_group_label>
    <arm_group_label>Low Fat</arm_group_label>
    <arm_group_label>Phase 2 tablet</arm_group_label>
    <other_name>PTI-125</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, Ages ≥ 18 and ≤ 45 years&#xD;
&#xD;
          2. BMI of 18 - 30 Kg/m²&#xD;
&#xD;
          3. Informed consent form (ICF) signed by the subject&#xD;
&#xD;
          4. General health status acceptable for participation in the study as determined by&#xD;
             medical history, review of current medication, physical examination, and laboratory&#xD;
             results&#xD;
&#xD;
          5. Fluency (oral and written) in English&#xD;
&#xD;
          6. The patient must agree to comply with the drawing of blood samples for the PK&#xD;
             assessments, laboratory assessments and plasma biomarkers&#xD;
&#xD;
          7. The subject is willing and able to remain at the study site for the duration of the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject has any relevant deviations from normal in physical examination,&#xD;
             electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the&#xD;
             investigator.&#xD;
&#xD;
          2. The subject has had a clinically significant illness within 30 days of this study.&#xD;
&#xD;
          3. The subject has a history of significant neurological, hepatic, renal, endocrine,&#xD;
             cardiovascular, gastrointestinal, pulmonary, or metabolic disease.&#xD;
&#xD;
          4. Subject is taking prescription CNS medication.&#xD;
&#xD;
          5. The subject has used alcohol, grapefruit, grapefruit juice, caffeine or&#xD;
             xanthinecontaining products 48 h before dosing or intends to use any of these products&#xD;
             during the study.&#xD;
&#xD;
          6. The subject has a history of substance abuse or a current positive ethanol breath test&#xD;
             or positive urine drug screen.&#xD;
&#xD;
          7. The subject has a positive serum hepatitis B surface antigen or positive HCV antibody&#xD;
             test.&#xD;
&#xD;
          8. The subject has a positive HIV test.&#xD;
&#xD;
          9. The subject has a current positive urine cotinine test.&#xD;
&#xD;
         10. The subject has participated in another drug study in the past 30 days.&#xD;
&#xD;
         11. The subject has donated or lost a significant volume of blood (&gt;450 mL) within 4 weeks&#xD;
             of the study.&#xD;
&#xD;
         12. The subject is unwilling to reside in the study unit for the duration of the study or&#xD;
             to cooperate fully with the investigator or site personnel.&#xD;
&#xD;
         13. Covid-19 infection within the past 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials Phase I Unit</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>June 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 12, 2021</last_update_submitted>
  <last_update_submitted_qc>June 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

